Figure 1 The burden of chronic kidney disease (CKD)

Slides:

Advertisements

Similar presentations

A.M. Thompson, T.G. Pickering Kidney International

Advertisements

ANZDATA Registry 39th Annual Report Chapter 13: End Stage Kidney Disease in Aotearoa/New Zealand Data to 31-Dec-2015.

Figure 1 Disruption of phosphate homeostasis in chronic kidney disease (CKD) Figure 1 | Disruption of phosphate homeostasis in chronic kidney disease (CKD).

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 5 Inter-relationships between sleep apnoea, CKD and brain injury Figure 5 | Inter-relationships between sleep apnoea, CKD and brain injury. In chronic.

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Differences in glycaemic control with the study drug

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 1 Types of coronary artery calcification

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.

Figure 1 Role of the kidney in glucose homeostasis

Figure 3 The fat–intestine–kidney axis

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Mitchell H. Rosner, W. Kline Bolton Kidney International

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 2 Milestones in paediatric acute kidney injury (AKI) research

Figure 1 Acute kidney injury and chronic kidney disease

Figure 4 The gut–kidney axis, inflammation and cardiovascular disease in CKD Figure 4 | The gut–kidney axis, inflammation and cardiovascular disease in.

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

CHAPTER 1 All Renal Replacement Therapy In Malaysia

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Specificity of the various epidermal growth factor (EGF)

The Challenge of Providing Renal Replacement Therapy in Developing Countries: The Latin American Perspective Gregorio T. Obrador, MD, MPH, Ximena Rubilar,

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Localization of ErbB receptors and ligands within the nephron

Andrew Narva American Journal of Kidney Diseases

Figure 3 Hypothetical trajectories of acute kidney disease (AKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Nat. Rev. Cardiol. doi: /nrcardio

Figure 6 Combining population-wide and high-risk strategies

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Volume 70, Issue 11, Pages (December 2006)

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Figure 4 Intracellular distribution and

Figure 1 Worldwide distribution of disease burden attributable to environmental risks in 2012 Figure 1 | Worldwide distribution of disease burden attributable.

Targeting Immunity in End-Stage Renal Disease

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Nat. Rev. Nephrol. doi: /nrneph

Rajni Singhal, Janet E. Hux, Shabbir M H Alibhai, Matthew J. Oliver

Presentation transcript:

Figure 1 The burden of chronic kidney disease (CKD) Figure 1 | The burden of chronic kidney disease (CKD)*. a | Percentage distribution of the various stages of CKD. b | CKD in the global population. The fraction of patients who undergo renal replacement therapy (RRT) is very small. *Global approximations, extracted from various databases5,12–18. Vanholder, R. et al. (2017) Reducing the costs of chronic kidney disease while delivering quality health care: a call to action Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.63